Cyclacel Pharmaceuticals Files 8-K
Ticker: BGMSP · Form: 8-K · Filed: Apr 25, 2025 · CIK: 1130166
Sentiment: neutral
Topics: corporate-governance, financial-statements
Related Tickers: CYCC
TL;DR
Cyclacel filed an 8-K for corporate updates and financials.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an 8-K on April 25, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as Xcyte Therapies Inc., is incorporated in Delaware and has its fiscal year end on December 31st. The filing does not contain specific financial figures or details about the amendments.
Why It Matters
This filing indicates updates to Cyclacel Pharmaceuticals' corporate structure or bylaws and the submission of financial statements, which are important for investors to understand the company's governance and financial health.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific amendments were made to Cyclacel Pharmaceuticals' articles of incorporation or bylaws?
The filing does not specify the exact nature of the amendments to the articles of incorporation or bylaws.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 25, 2025.
What is Cyclacel Pharmaceuticals' fiscal year end?
Cyclacel Pharmaceuticals' fiscal year ends on December 31st.
What was Cyclacel Pharmaceuticals' former company name?
Cyclacel Pharmaceuticals' former company name was XCYTE THERAPIES INC.
What is the Commission File Number for Cyclacel Pharmaceuticals?
The Commission File Number for Cyclacel Pharmaceuticals is 000-50626.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 25, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).